BRCA2 and prostate carcinoma: We note in this case a heterogeneous response to abiraterone acetate may be related to the somatic <i>BRCA2</i> deletions.<h4>Conclusions</h4>We present the first Japanese case of a metastatic abiraterone acetate-resistant castration-resistant prostate cancer accompanied by BRCA2 mutation.